Additionally, if gut permeability is indeed increased in ME/CFS patients, microbes and antigens may be able to cross the epithelial barrier into surrounding tissue and blood, potentially crossing the BBB and altering the HPA axis (443)
Goal: Type 2 diabetes management (A1C reduction) If you prefer once-weekly injections: Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), or efpeglenatide (Eperzan) If you prefer daily injections: Liraglutide (Victoza) or lixisenatide (Adlyxin) If you prefer oral medication: Semaglutide (Rybelsus) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide (if eligible under shortage provisions) Goal: Weight loss (obesity or overweight with comorbidities) If you want maximum weight loss: Retatrutide (Retara, triple agonist, 24% mean loss) or tirzepatide (Zepbound, dual agonist, 20% to 22% mean loss) If you want proven long-term safety data: Semaglutide (Wegovy, 15% to 17% mean loss, 5+ years post-approval data) If you prefer oral medication: Orforglipron (Orfoglip, 15% mean loss, oral once daily) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide Goal: Both diabetes and weight loss If you have significant obesity (BMI over 35): Tirzepatide (Mounjaro for diabetes indication, Zepbound for obesity indication
Skin and wound health: GHK-CU is known for its ability to improve skin appearance and aid in wound healing
21 Mar 2013
( E ) 405/488 nm ratios of iRBCs, RBCs, and the mean fluorescence ratios of iRBCs subtracted from the ratios of RBCs (n = 3)
Medications That May Disqualify or Limit GLP-1 Use Certain medications interact with GLP-1 receptor agonists or create safety concerns that may limit your eligibility
